StockData
Akari Therapeutics Plc logo

Akari Therapeutics Plc (AKTX) company profile

AKTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 0/30
$5.70−0.81 (-12.44%)

Close on Nov 17, 2026Market cap $11.10MP/E –Yield –

About Akari Therapeutics

Pharmaceutical Preparations, SIC 2834

The provided text does not contain factual descriptions or narrative details concerning what the company does, its specific products, operational segments, or customer base. The text consists entirely of XBRL metadata tags, SEC filing identifier codes, dates, and accounting taxonomy members relating to shares, notes, and warrants.

Similarly, no information is provided regarding the company's operating scale, store count, geographical presence, or headquarters location. While ticker symbols and entity members such as AKTX and Peak Bio appear within the raw data strings, the excerpt contains no descriptive prose from which a business profile or operational facts can be derived.

Summary of the business section of Akari Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Akari Therapeutics Plc
Headquarters
Tampa, FL
Address
401 East Jackson Street, Suite 3300 33602
Phone
(929) 274-7510
Employees
6, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
X0
Fiscal year ends
December 31
Auditor
BDO USA, P.C., New York, New York

Stock & identifiers

Ticker
AKTX
Former tickers
CLTX until Nov 23, 2015; CLSXY until Mar 24, 2014
Exchange
Nasdaq
IPO date
Jan 6, 2014
Shares outstanding
155.76B, Aug 13, 2026
Public float
$15.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-40 reverse, Mar 31, 2026; 1-for-20 reverse, Aug 17, 2023; 13-for-1, Nov 23, 2015; 1-for-10 reverse, Sep 17, 2015
SEC CIK
1541157
CUSIP
00972G405
ISIN
US00972G4055
FIGI
BBG003PMV495
Share class FIGI
BBG003PMV510
LEI
2138001XURASAU3MEB68
EIN
98-1034922

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Abizer GaslightwalaCEO, Director41,173
Vatnak Vat-HoChief Business Officer–
Kameel D. FaragInterim CFO23,309
Torsten HombeckCFO200
Robert B. BazemoreDirector22,759
Raymond Prudo-ChleboszDirector496,599
Samir Rashmikant PatelDirector110,343
Hoyoung HuhDirector250,262
Sandip I. PatelDirector99,127
James R. NealDirector36,271

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Peo1
$1.66M$485.93K$369.70K$3–
FY2025
Peo2
$324.99K$324.99K$369.70K$3–
FY2024
Peo1
$435.77K$435.77K$436.67K$4–
FY2024
Peo2
$435.77K$435.77K$436.67K$4–
FY2023$1.56M$979.80K$222.59K$10–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“of March 1, 2026, we had 6 employees, 5 of which are full-time, including our Chief Executive Officer, Abizer Gaslightwala, our Executive”

Corporate history

Events identified from SEC filings

DateEventDetails
May 18, 2026Late filingNotification of late filing
Nov 26, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 31, 2025Late filingNotification of late filing
Nov 15, 2024Late filingNotification of late filing
Nov 14, 2024Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Nov 14, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 4, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Sep 13, 2024MergerRegistration of securities for a merger or exchange offer (S-4)
Aug 15, 2024Late filingNotification of late filing
Apr 11, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 29, 2022Late filingNotification of late filing
May 1, 2018Late filingNotification of late filing
Apr 8, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 24, 2015Auditor changeChange in certifying accountant (8-K Item 4.01)
Nov 17, 2015Late filingNotification of late filing
Sep 21, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Sep 15, 2015Name changeName changed from Celsus Therapeutics Plc. to Akari Therapeutics Plc
Aug 3, 2015Merger voteDefinitive merger proxy statement
Apr 13, 2015Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 30, 2014ListingRegistration of securities on an exchange (Form 8-A)
Jun 20, 2013Name changeName changed from Morria Biopharmaceuticals PLC to Celsus Therapeutics Plc.

See a number that looks wrong?